Author Correction: A global database of COVID-19 vaccinations

Abstract

In the version of this article initially published, errors occurred in Figs. 2 and 6. Figure 2 showed a lack of alignment between the years presented on gross domestic product (GDP) per capita values across countries. These figures-presented in GDP per capita adjusted for purchasing power parity, measured in international dollars-have now been aligned. This correction was necessary because the most recent year for which GDP data is available from the World Bank is different across countries. The GDP alignment issue will have affected all countries in the dataset, some to a very small (unnoticeable) degree when GDP has not significantly changed year-to-year, but more visibly for countries with strong growth rates (e.g., China). Figure 6 incorrectly indicated that no vaccine for Ebola exists. In fact, the first vaccine against Ebola was approved in the European Union and the USA in 2019. These errors have been corrected in the PDF and HTML versions of this article.

Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

“…Fifteen months on from the administration of the first experimental COVID-19 vaccine doses to humans in March 2020, there is now a global race against the causative virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to deploy vaccines to control the pandemic 1 , with differing levels of vaccine rollout in different countries ( Our World in Data ). Despite authorization having been granted for multiple vaccines, as the ongoing global outbreaks demonstrate, the pandemic is far from over.…”

Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2

“…The decline in new infection rates in many countries coincides with the introduction of vaccines. However, COVID-19 cases continue to emerge, probably due to the appearance and evolution of novel SARS-CoV-2 variants, the decline of immunological protection provided by the current vaccines, and, especially, the lack of homogenous distribution of COVID-19 vaccines, with only 4.4% of people in low-income countries having received at least one dose (November 2021) (Hannah Ritchie et al ., 2020; Mathieu et al ., 2021). As the global outbreak continues, the pandemic is far from being over, and it is not clear if the available vaccines will be sufficient to revert the situation.…”

Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: Coronavac vs. Astrazeneca vs. Pfizer

“…This section illustrates the application of the proposed RBCBA approach to the specific case of COVID-19 in Brazil and the vaccines CV, AZ, and PF from August 31 th 2021 to March 3 rd 2022. The input data for the model were collected from February 26 th , 2020 to August 30 th , 2021, in Brazil from a public database i.e., the Our World in Data (OWD) COVID-19 database [33] . Next, we present the detailed results of each step of the RBCBA.…”

“…We processed the input data and estimated that million people on average receive the second dose of vaccines per week, and we denote this parameter as [33] . We can also assess different VSs by changing this rate; Table 3 summarizes the VSs.…”